Caraco Pharmaceutical Laboratories Ltd

Caraco Pharmaceutical Laboratories — Investor Presentation (February 2007)

21 slides from Caraco Pharmaceutical Laboratories's investor presentation, Feb 8, 2007

  1. Slide 1: Caraco Pharmaceutical Laboratories, Ltd.

    Slide 1: Caraco Pharmaceutical Laboratories, Ltd.

    Caraco Pharmaceutical Laboratories, Ltd.

  2. Slide 2: Safe Harbor

    Slide 2: Safe Harbor

    Safe Harbor: This presentation contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual re

  3. Slide 3: Overview: What sets us apart from the pack?

    Slide 3: Overview: What sets us apart from the pack?

    Caraco Overview What sets us apart from the pack? Size of our Product Portfolio vs. the Size of Company Experienced Management Team Vertically Integrated via Sun API’s Disciplined Management Ability to Service our Customers’ Immediate Needs Capable of Creating Markets that Previously did not Exist

  4. Slide 4: Overview: What sets us apart from the pack?

    Slide 4: Overview: What sets us apart from the pack?

    Caraco Overview What sets us apart from the pack? Diverse Paths of Development Building to fit the Current Environment Improved Customer Mix Removal of Barriers, Execution Ability to Penetrate the Market

  5. Slide 5: Annual Historical Results

    Slide 5: Annual Historical Results

    Caraco Pharmaceutical Laboratories, Ltd. Annual Historical Results (in US $ millions) *Change in fiscal year

  6. Slide 6: Quarterly Analysis

    Slide 6: Quarterly Analysis

    Caraco Pharmaceutical Laboratories, Ltd. Quarterly Analysis (in US $ millions)

  7. Slide 7: Sales for Fiscal 2007 (YTD)

    Slide 7: Sales for Fiscal 2007 (YTD)

    Caraco Pharmaceutical Laboratories, Ltd. SALES for Fiscal 2007 (YTD) (in US $ millions) * Change in fiscal year

  8. Slide 8: Product Development Quarterly Filings (ANDAs)

    Slide 8: Product Development Quarterly Filings (ANDAs)

    Caraco Pharmaceutical Laboratories, Ltd. Product Development Quarterly Filings (ANDAS) *Includes two tentative FDA approvals

  9. Slide 9: Product Market Share Trends

    Slide 9: Product Market Share Trends

    Caraco Pharmaceutical Laboratories, Ltd. Product Market Share Trends Caraco is Currently Marketing 27 Generic Pharmaceuticals and One Brand Product One of the 27 Products was Launched in the Third Quarter of Fiscal 2007 Eight of the 27 Products are in the Top Three of Generic Market Share Tramadol w

  10. Slide 10: Product Market Share Trends

    Slide 10: Product Market Share Trends

    Caraco Pharmaceutical Laboratories, LTD Product Market Share Trends ZONISAMIDE Zonegran ® BACLOFEN Lioresal ® TIZANIDINE Zanaflex ® DIGOXIN Lanoxin ® TRAMADOL W/ APAP Ultracet ® CLONAZEPAM Klonopin ® TRAMADOL Ultram ® PAROMOMYCIN** Humatin ® CHOLINE MAG Trilisate ® GLIPIZIDE Glucotrol ® TICLOPIDINE

  11. Slide 11: Net Sales by Trade Class

    Slide 11: Net Sales by Trade Class

    Caraco Pharmaceutical Laboratories, Ltd. Net Sales by Trade Class

  12. Slide 12: Net Sales by Trade Class

    Slide 12: Net Sales by Trade Class

    Caraco Pharmaceutical Laboratories, Ltd. Net Sales by Trade Class Growth Percentages Chain : 244.7% Dist : 21.5% Whole : 122.9% Mg Care : 50.5% Govt : 15.4%

  13. Slide 13: Third Quarter Fiscal 2007 Highlights

    Slide 13: Third Quarter Fiscal 2007 Highlights

    Third Quarter Fiscal 2007 Highlights Signed Two Definitive Agreements (One During 3Q’07 and One After the Close of 3Q’07) Bringing Total to Three Definitive Agreements Signed with Third Party Developers or Formulators Launched One Product - Phenytoin Filed Two Products with FDA Bringing Total Produc

  14. Slide 14: Third Quarter Fiscal 2007 Highlights

    Slide 14: Third Quarter Fiscal 2007 Highlights

    Third Quarter Fiscal 2007 Highlights Third Quarter Net Sales Growth of 51% Year-over-Year (YTD 45%) Gross Profit 48% Successive Quarterly Growth of 11%

  15. Slide 15: Expansion

    Slide 15: Expansion

    Expansion Current Owned Facilities are 114,000 sq ft and Lease Another 67,000 sq ft for Total Footprint of Approximately 180,000 sq ft Need to Build 100,000 - 125,000 sq ft Facility or Move to 250,000 sq. ft cGMP Facility for Complete Company Move Fiscal 2007 forecast is for an average of 300 millio

  16. Slide 16: Accomplishments Year-to-Date

    Slide 16: Accomplishments Year-to-Date

    Accomplishments Year-to-Date Fiscal 2007 YTD Fiscal 2007; Filed 7 Products with the FDA Maintained Gross Profit of Approximately 49%, which is Above the Generic Industry Average Recognized by One of the “Big Three Wholesalers” in US as Best Trade Representative for Companies Under $100 Million in Sa

  17. Slide 17: Clozapine Sales Update & Web Registry Development

    Slide 17: Clozapine Sales Update & Web Registry Development

    Caraco Pharmaceutical Laboratories, Ltd. Clozapine Sales Update & Web Registry Development Caraco successfully launched www.caracoclozapine.com on March 20 th 2006 30% Increase in Registered Pharmacies and 88% increase in Registered Clients, since the Website’s Inception

  18. Slide 18: Product Litigation

    Slide 18: Product Litigation

    Product Litigation Lexapro – Teva/IVAX Lost First Case, Teva Appealed Decision on November 6, 2006; Possible Upside if Caraco Prevails. Forest was Denied Motion to Transfer its Action Against Caraco to the United States District Court for the District of Delaware; the Litigation will Proceed in East

  19. Slide 19: Drivers Fiscal 2007

    Slide 19: Drivers Fiscal 2007

    Drivers Fiscal 2007 Approvals - Phenytoin Pending Approvals Increase / Maintain Share Increase and Close Alternate Development Projects

  20. Slide 20: Drivers Fiscal 2007

    Slide 20: Drivers Fiscal 2007

    Drivers Fiscal 2007 Expand Current Development Streams and Pursue New Opportunities Expansion of Current Facilities Improve Packaging Continue Staff Improvements and Succession Planning

  21. Slide 21: Thank You

    Slide 21: Thank You

    CARACO Thank You

Source: SEC EDGAR · 8-K filed Feb 8, 2007

More decks from Caraco Pharmaceutical Laboratories Ltd